News 01.07.2026 PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused...
News 29.06.2026 Neurimmune announced today that safety and efficacy data of the long-term follow up of the NI006-101 trial of cliramitug (formerly NI006, ALXN2220) for the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM) have been published in Nature Medicine by Peter C. Kahr et al.1 ATTR-CM is a systemic and potentially life-threatening disease caused by...
News 23.06.2026 Switzerland, 23 June 2026 – CUTISS, a late-stage clinical company at the forefront of tissue therapeutics and regenerative medicine, has announced the election of Dr. Achim von Leoprechting as Chairman of its Board of Directors. Dr. von Leoprechting succeeds Prof. Martin Meuli, co-founder, who has chaired the CUTISS Board since the company’s...
News 11.06.2026 Lightium is this year's winner of the Swiss Economic Award. Through this competition, the Swiss Economic Forum (SEF) and its partners—Helbling, Swisscom, and UBS—support young business talent in Switzerland. Nine finalists presented their business models to the main jury and the audience at the SEF, which took place on June...
News 08.06.2026 Schlieren / Zurich, Switzerland, 5 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today shared additional data analysis from its Phase II study of potravitug at the European Renal Association (ERA) Congress. The oral presentation detailed findings...